A clinical-stage biotech designing tissue-specific therapies for cancer and inflammatory diseases, currently testing its lead drug IMX-110 in Phase 1b/2a trials for solid tumors alongside a partnership with BeiGene.
No revenue yet—the company burns cash, posting operating losses of USD 0.03B in 2025, USD 0.02B in 2024, and USD 0.02B in 2023, with zero gross margin.
Weak: no approved products or proprietary platform proven in late-stage trials; larger players like Merck and Bristol Myers Squibb dominate oncology, and clinical failure or competition could erase any edge.
Key events, in time order
None yet
None yet
Immix Biopharma ($IMMX) is experiencing strong upward momentum, hitting 52-week highs, indicating a positive trend in the healthcare sector.
Main discussion
$IMMX Another portfolio winner pushing 52‑week highs — trimmed at $13.4+. And just yesterday, $IOVA printed fresh 52‑week highs as well 🙏🙏
Stocks hitting fresh 52-week highs, highlighting strong momentum across technology, industrials, and healthcare, with PEG and P/S included to help assess growth and valuation. $WEX $PAYS $FLYW $RHI $MFP $MAN $GEO $CYRX $XNCR $TXG $TWST $TVTX $THC $PSNL $OGN $NEO $MRVI $MRK $IMMX
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
